Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial

The Lancet Oncology

Volumn 15, Issue 7, 2014, Pages 700-712

  Kwon, Eugene D ^a   Drake, Charles G ^b   Scher, Howard I ^c   Fizazi, Karim ^d   Bossi, Alberto ^d   Van den Eertwegh, Alfons J M ^e   Krainer, Michael ^f   Houede, Nadine ^g,h   Santos, Ricardo ⁱ   Mahammedi, Hakim ^j   Ng, Siobhan ^k   Maio, Michele ^l   Franke, Fabio A ^m   Sundar, Santhanam ⁿ   Agarwal, Neeraj ^o   Bergman, Andries M ^p   Ciuleanu, Tudor E ^q   Korbenfeld, Ernesto ^r   Sengeløv, Lisa ^s   Hansen, Steinbjorn ^t   Logothetis, Christopher ^u   Beer, Tomasz M ^v   McHenry, M Brent ^w   Gagnier, Paul ^w   Liu, David ^w   Gerritsen, Winald R ^x   more..

^a MAYO CLINIC   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g INSTITUT BERGONIÉ   (France)

^h DEPARTMENT OF NEUROLOGY   (France)

ⁱ Centro Médico Austral   (Argentina)

^j CENTRE JEAN PERRIN   (France)

^k ST JOHN OF GOD HOSPITAL   (Australia)

^l UNIVERSITY HOSPITAL OF SIENA   (Italy)

^m Associacao Hospital de Caridade Ijui   (Brazil)

ⁿ NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^o UNIVERSITY OF UTAH   (United States)

^p ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^q IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^r HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^s GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^t ODENSE UNIVERSITY HOSPITAL   (Denmark)

^u UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^v OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^w BRISTOL MYERS SQUIBB   (United States)

^x RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; DOCETAXEL; HEMOGLOBIN; IPILIMUMAB; PLACEBO; TRIACYLGLYCEROL LIPASE;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; AGED; ANEMIA; ARM PAIN; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EFFECTIVENESS; COLITIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEVER; FOLLOW UP; GENERAL CONDITION DETERIORATION; HAZARD RATIO; HEADACHE; HEPATITIS; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTHYROIDISM; INSOMNIA; INTENTION TO TREAT ANALYSIS; LEG PAIN; LIVER TOXICITY; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MOTOR DYSFUNCTION; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; THORAX PAIN; TREATMENT DURATION; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS;

EID: 84901641673     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70189-5     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008, 26:1148-1159.
3. Horwich A, Hugosson J, de Reijke T, et al. Prostate cancer: ESMO Consensus Conference guidelines 2012. Ann Oncol 2013, 24:1141-1162.
4. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154. for the TROPIC Investigators.
5. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012, 13:983-992. for the COU-AA-301 Investigators.
6. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-1197. for the AFFIRM Investigators.
7. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013, 369:213-223. for the ALSYMPCA Investigators.
8. Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 2001, 98:14565-14570.
9. Bronte V, Kasic T, Gri G, et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 2005, 201:1257-1268.
10. Sfanos KS, Bruno TC, Meeker AK, De Marzo AM, Isaacs WB, Drake CG Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate 2009, 69:1694-1703.
11. Kiniwa Y, Miyahara Y, Wang HY, et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 2007, 13:6947-6958.
12. Diener KR, Woods AE, Manavis J, Brown MP, Hayball JD Transforming growth factor-β-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression. Lab Invest 2009, 89:142-151.
13. Degl'Innocenti E, Grioni M, Boni A, et al. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur J Immunol 2005, 35:66-75.
14. Drake CG Immunotherapy for prostate cancer: emerging treatment modality. Urol Clin North Am 2010, 37:121-129.
15. Kwon ED, Hurwitz AA, Foster BA, et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 1997, 94:8099-8103.
16. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422. for the IMPACT Study Investigators.
17. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010, 28:1099-1105.
18. Fong L, Small EJ Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008, 26:5275-5283.
19. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
20. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
21. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012, 18:2039-2047.
22. Lebbé C, Weber JS, Maio M, et al. Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials. Proc Am Soc Clin Oncol 2013, 31(suppl 15). abstract 9053.
23. Maio M, Bondarenko I, Robert C, et al. Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma. European Cancer Congress 2013; Amsterdam, Netherlands; Sept 27 to Oct 1, 2013. (abstr) 3704.
24. Kwon ED, Foster BA, Hurwitz AA, et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci USA 1999, 96:15074-15079.
25. Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13:501-508.
26. van den Eertwegh AJ, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13:509-517.
27. Slovin S, Higano CS, Hamid O, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013, 24:1813-1821.
28. Harris TJ, Hipkiss EL, Borzillary S, et al. Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate 2008, 68:1319-1329.
29. Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003, 170:6338-6347.
30. Kaur P, Asea A Radiation-induced effects and the immune system in cancer. Front Oncol 2012, 2:191.
31. Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004, 58:862-870.
32. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012, 366:925-931.
33. Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005, 97:798-804.
34. Kaplan EL, Meier P Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
35. Brookmeyer R, Crowley J A confidence interval for the median survival time. Biometrics 1982, 38:29-41.
36. Fleming TR, Harrington DP Counting processes and survival analysis 1991, John Wiley and Sons, New York.
37. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010, 11:155-164.
38. Weber JS, Kähler KC, Hauschild A Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012, 30:2691-2697.
39. Princeton: Bristol-Myers Squibb, 2013 Yervoy (ipilimumab) package insert, (accessed Jan 14, 2014). http://packageinserts.bms.com/pi/pi_yervoy.pdf.